Continued Conversation on the State of Access to Women’s Health Care
FOR IMMEDIATE RELEASE Currently, there are over 167.5 million women (including individuals who identify as women or have the propensity to menstruate) living in the U.S. An estimated 3% of them are living with a diagnosed…
Matt Hartnett
Matthew Hartnett, BS, MPH, is the community network research manager for the NBDF, where he focuses on Community Voices in Research (CVR), a community-powered registry for the bleeding disorders community. Matt obtained his undergraduate degree in…
National Hemophilia Foundation Celebrates 50 Years of the Judith Graham Pool Fellowship
MEDIA CONTACT:  Ilana Ostrin  212-328-3769  iostrin@hemophilia.org    November 14, 2022 — New York, NY — This fall, the National Hemophilia Foundation (NHF) is thrilled to…
New Document to Help Residential Substance Use Disorder Placement for Individuals with Bleeding Disorders
Historically, many residential substance use disorder (SUD) facilities have denied admittance to individuals with bleeding disorders – the basis of these denials are most often the use of self-administered, intravenous medications such a as factor…
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays Speaker(s): Lucy Lee NHF's Wednesday Webinars are a free…
Efanesoctocog: A Truly Long-Acting FVIII Replacement Product
Efanesoctocog: A Truly Long-Acting FVIII Replacement Product Speaker(s): Dr. Barb Konkle NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
NHF kicks off the season of giving with Giving Shoesday
FOR IMMEDIATE RELEASE  MEDIA CONTACT:                                                                                  Ilana Ostrin      Senior Director of Public Relations and CommunicationsThe National Hemophilia…
First Hemophilia B Gene Therapy Approved by FDA
On November 22, the U.S. Food and Drug Administration approved HEMGENIX (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX…
NHF Board of Directors Meeting | 2022 December
 We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on December 1st starting at 7:00 pm ET. This meeting will discuss NHF business operations and decisions and…
Development of Hematopoietic CRISPR/Cas9 Gene Activation for Hemophilia Therapy
Dr. Satish Nandakumar is currently a postdoctoral fellow in the laboratory of Dr. Vijay Sankaran at the Boston Children's Hospital. Previously, he did his graduate work at the St. Jude's Children's Research Hospital in Memphis, Tennessee. In his JGP…